CD56 (also known as NCAM, neural cell adhesion molecule) is an adhesion molecule that is mainly expressed on neurons, natural killer (NK) cells, as well as on the surface of various neuroendocrine tumor cells and small cell lung cancer cells. In tumor tissues, high expression of CD56 is usually closely associated with the adhesive, invasive, and metastatic capabilities of tumor cells. Lorvotuzumab (also known as IMGN901 or huN901) is a humanized monoclonal antibody derived from the murine monoclonal antibody N901, constructed by grafting the murine variable regions onto a human IgG framework. This antibody belongs to the humanized IgG1κ subtype and primarily targets the CD56 molecule. In studies, it is mostly investigated in the form of antibody–drug conjugates (ADCs), such as Lorvotuzumab-MMAE (F1839) and Lorvotuzumab mertansine (F1128). At present, Lorvotuzumab is mainly used in research related to CD56-positive tumors, such as small cell lung cancer, Merkel cell carcinoma, and certain multiple myelomas.
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Host
CHO
Alternative Names
hLorvotuzumab, IMGN901
Buffer System
100 mM Pro 20 mM Arg pH 5.0.
Target Accession
P13591
Reactivity
Human
Conjugation
Unconjugated
Clonality
Monoclonal
Purification
Protein A
Isotype
IgG1
Application
ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological Activity
TT Cell Line were stained with Anti-NCAM1/CD56 Antibody (Lorvotuzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, The EC50 is 0.015 ug/mL.
